BESPONSA 1 mg powder for concentrate for solution for infusion
Sponsors
Karolinska University Hospital, Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), Pfizer Inc., Fondazione Gimema Franco Mandelli Onlus, Fundacion PETHEMA
Conditions
Acute B-cell Lymphoblastic Leukemia with minimal residual positive disease prior to haematopoietic stem cell transplantation in adult patientsAcute Lymphoblastic LeukaemiaAcute Lymphoblastic Leukemia (ALL)Acute lymphoblastic leukaemiapediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia
Phase 1
Phase 2
B1931036 - A prospective, randomized, open-label phase 2 study to evaluate the superiority of Inotuzumab Ozogamicin monotherapy versus ALLR3 for induction treatment of childhood high risk first relapse B-cell precursor Acute Lymphoblastic Leukaemia
RecruitingCTIS2023-509810-13-00
Start: 2023-05-13Target: 94Updated: 2025-10-27
ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) with Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL)
RecruitingCTIS2022-501050-11-01
Start: 2020-07-13Target: 5943Updated: 2025-12-17
A Phase IIA Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin (IO) in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with positive Minimal Residual Disease before any Hematopoietic Stem Cell Transplantation. ALL2418
RecruitingCTIS2023-510516-39-00
Start: 2019-10-30Target: 76Updated: 2024-12-03
Multicenter, open label, phase II clinical trial of inotuzumab ozogamicin as prophylaxis for relapse in patients with high-risk acute B-cell precursor acute lymphoblastic leukaemia after allogeneic stem cell haemotopoietic transplantation
Not yet recruitingCTIS2026-525964-17-00
Target: 30Updated: 2026-09-15